{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:06:58Z","timestamp":1791256018443,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011983","name":"American Radium Society","doi-asserted-by":"publisher","award":["6612-32000-067-00D"],"award-info":[{"award-number":["6612-32000-067-00D"]}],"id":[{"id":"10.13039\/100011983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["C0809-31400784"],"award-info":[{"award-number":["C0809-31400784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2018.06.055","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T06:07:22Z","timestamp":1530338842000},"page":"4846-4850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"PB","title":["Generation of a recombinant Newcastle disease virus expressing two foreign genes for use as a multivalent vaccine and gene therapy vector"],"prefix":"10.1016","volume":"36","author":[{"given":"Haixia","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.06.055_b0005","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s00705-017-3311-7","article-title":"Taxonomy of the order Mononegavirales: update 2017","volume":"162","author":"Amarasinghe","year":"2017","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0010","series-title":"Diseases of poultry","first-page":"98","article-title":"Newcastle Disease","author":"Miller","year":"2013"},{"key":"10.1016\/j.vaccine.2018.06.055_b0015","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.2460\/javma.2003.222.1534","article-title":"Avian influenza and Newcastle disease","volume":"222","author":"Swayne","year":"2003","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2018.06.055_b0020","series-title":"The biology of paramyxoviruses","first-page":"69","article-title":"Newcastle disease and ralated avian paramyxoviruses","author":"Samal","year":"2011"},{"key":"10.1016\/j.vaccine.2018.06.055_b0025","series-title":"Fields virology","first-page":"957","article-title":"Paramyxoviridae","author":"Lamb","year":"2013"},{"key":"10.1016\/j.vaccine.2018.06.055_b0030","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s007050070059","article-title":"Genome replication of Newcastle disease virus: involvement of the rule-of-six","volume":"145","author":"Peeters","year":"2000","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0035","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J Virol"},{"issue":"Pt 11","key":"10.1016\/j.vaccine.2018.06.055_b0040","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1099\/0022-1317-80-11-2987","article-title":"Generation of recombinant lentogenic Newcastle disease virus from cDNA","volume":"80","author":"Romer-Oberdorfer","year":"1999","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0045","first-page":"46","article-title":"Newcastle disease virus as a vaccine vector for humans","volume":"10","author":"Bukreyev","year":"2008","journal-title":"Curr Opin Mol Therap"},{"key":"10.1016\/j.vaccine.2018.06.055_b0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ps\/82.6.899","article-title":"Recombinant Newcastle disease virus as a vaccine vector","volume":"82","author":"Huang","year":"2003","journal-title":"Poult Sci"},{"key":"10.1016\/j.vaccine.2018.06.055_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/v8070183","article-title":"Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines","volume":"8","author":"Kim","year":"2016","journal-title":"Viruses"},{"issue":"18","key":"10.1016\/j.vaccine.2018.06.055_b0060","first-page":"5 1","article-title":"Reverse genetics for newcastle disease virus as a vaccine vector","volume":"48","author":"Kim","year":"2018","journal-title":"Curr Protoc Microbiol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-1-59745-561-9_30","article-title":"Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer","volume":"542","author":"Schirrmacher","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0070","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1038\/mt.2008.181","article-title":"Recombinant Newcastle disease virus as a vaccine vector for cancer therapy","volume":"16","author":"Vigil","year":"2008","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"10.1016\/j.vaccine.2018.06.055_b0075","first-page":"15","article-title":"Have we found an optimal insertion site in a Newcastle disease virus vector to express a foreign gene for vaccine and gene therapy purposes?","volume":"2","author":"Yu","year":"2015","journal-title":"Brit J Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0080","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1099\/vir.0.000142","article-title":"Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism","volume":"96","author":"Zhang","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0085","doi-asserted-by":"crossref","first-page":"8624","DOI":"10.1016\/j.vaccine.2011.09.007","article-title":"Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroup C as a bivalent vaccine in turkeys","volume":"29","author":"Hu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.055_b0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.virusres.2007.07.008","article-title":"Evaluation of Newcastle disease virus chimeras expressing the Hemagglutinin-Neuraminidase protein of velogenic strains in the context of a mesogenic recombinant virus backbone","volume":"129","author":"Estevez","year":"2007","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.06.055_b0095","series-title":"A laboratory manual for the isolation and identification of avian pathogens","first-page":"156","article-title":"Newcastle disease virus and other avian paramyxoviruses","author":"Alexander","year":"1998"},{"key":"10.1016\/j.vaccine.2018.06.055_b0100","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1128\/JVI.01946-09","article-title":"Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys","volume":"84","author":"DiNapoli","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1637\/11632-032017-ResNoteR","article-title":"Infectious bronchitis virus S2 of 4\/91 expressed from recombinant virus does not protect against ark-type challenge","volume":"61","author":"Eldemery","year":"2017","journal-title":"Avian Dis"},{"key":"10.1016\/j.vaccine.2018.06.055_b0110","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.vaccine.2015.03.091","article-title":"Recombinant Newcastle disease viral vector expressing hemagglutinin or fusion of canine distemper virus is safe and immunogenic in minks","volume":"33","author":"Ge","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.055_b0115","doi-asserted-by":"crossref","first-page":"10054","DOI":"10.1128\/JVI.78.18.10054-10063.2004","article-title":"A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV","volume":"78","author":"Huang","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0120","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2014.04.068","article-title":"A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens","volume":"32","author":"Kanabagatte Basavarajappa","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.055_b0125","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1128\/JVI.01570-14","article-title":"Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice","volume":"88","author":"Kim","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.virol.2012.06.001","article-title":"Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs","volume":"432","author":"Kong","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.06.055_b0135","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.vaccine.2008.02.061","article-title":"Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus","volume":"26","author":"Romer-Oberdorfer","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.055_b0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1637\/9539-092710-Reg.1","article-title":"Efficacy of Newcastle disease virus recombinant expressing avian influenza virus H6 hemagglutinin against Newcastle disease and low pathogenic avian influenza in chickens and turkeys","volume":"55","author":"Schroer","year":"2011","journal-title":"Avian Dis"},{"key":"10.1016\/j.vaccine.2018.06.055_b0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1637\/10641-081613-Reg.1","article-title":"Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge","volume":"58","author":"Toro","year":"2014","journal-title":"Avian Dis"},{"key":"10.1016\/j.vaccine.2018.06.055_b0150","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.vaccine.2016.12.038","article-title":"Newcastle disease virus vectored infectious laryngotracheitis vaccines protect commercial broiler chickens in the presence of maternally derived antibodies","volume":"35","author":"Yu","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.06.055_b0155","doi-asserted-by":"crossref","first-page":"8397","DOI":"10.1128\/JVI.01321-14","article-title":"Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges","volume":"88","author":"Zhao","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0160","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1038\/s41598-017-04267-7","article-title":"Engineered Newcastle disease virus expressing the F and G proteins of AMPV-C confers protection against challenges in turkeys","volume":"7","author":"Hu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2018.06.055_b0165","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01005-15","article-title":"Mucosal immunization with Newcastle disease virus vector coexpressing HIV-1 Env and Gag proteins elicits potent serum, mucosal, and cellular immune responses that protect against vaccinia virus Env and Gag challenges","volume":"6","author":"Khattar","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2018.06.055_b0170","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1637\/9652-011111-Reg.1","article-title":"Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens","volume":"55","author":"Ramp","year":"2011","journal-title":"Avian Dis"},{"key":"10.1016\/j.vaccine.2018.06.055_b0175","first-page":"371","article-title":"Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes","volume":"15","author":"Puhler","year":"2008","journal-title":"GeneTher"},{"key":"10.1016\/j.vaccine.2018.06.055_b0180","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/viro.2000.0618","article-title":"Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation","volume":"278","author":"Krishnamurthy","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.06.055_b0185","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/viro.2000.0372","article-title":"Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes","volume":"272","author":"Skiadopoulos","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.06.055_b0190","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1128\/JVI.76.15.7642-7650.2002","article-title":"Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression","volume":"76","author":"Wertz","year":"2002","journal-title":"J Virol."},{"key":"10.1016\/j.vaccine.2018.06.055_b0195","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1099\/vir.0.18884-0","article-title":"Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication","volume":"84","author":"Zhao","year":"2003","journal-title":"J Gen Virol."},{"key":"10.1016\/j.vaccine.2018.06.055_b0200","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1099\/vir.0.068437-0","article-title":"P and M gene junction is the optimal insertion site in Newcastle disease virus vaccine vector for foreign gene expression","volume":"96","author":"Zhao","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0205","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1637\/7930-020807-REGR.1","article-title":"Evaluating viral interference between infectious bronchitis virus and Newcastle disease virus vaccine strains using quantitative reverse transcription-polymerase chain reaction","volume":"51","author":"Gelb","year":"2007","journal-title":"Avian Dis"},{"key":"10.1016\/j.vaccine.2018.06.055_b0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF02898716","article-title":"Multivalent vaccines: prospects and challenges","volume":"42","author":"Spier","year":"1997","journal-title":"Folia Microbiol (Praha)"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2018.06.055_b0215","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcpa.2007.04.014","article-title":"The nature and consequences of intra- and inter-vaccine interference","volume":"137","author":"Vidor","year":"2007","journal-title":"J Comp Pathol"},{"key":"10.1016\/j.vaccine.2018.06.055_b0220","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4161\/cbt.29686","article-title":"Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy","volume":"15","author":"Bai","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.vaccine.2018.06.055_b0225","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3892\/or.2016.4925","article-title":"Genetically engineered Newcastle disease virus expressing human interferon-lambda1 induces apoptosis in gastric adenocarcinoma cells and modulates the Th1\/Th2 immune response","volume":"36","author":"Bu","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.vaccine.2018.06.055_b0230","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7785\/tcrt.2012.500414","article-title":"Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model","volume":"14","author":"Niu","year":"2015","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.vaccine.2018.06.055_b0235","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1158\/0008-5472.CAN-07-1025","article-title":"Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus","volume":"67","author":"Vigil","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.06.055_b0240","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jphs.2016.03.012","article-title":"Recombinant Newcastle disease virus (NDV\/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy","volume":"132","author":"Wu","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2018.06.055_b0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2017.02.042","article-title":"Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy","volume":"802","author":"Wu","year":"2017","journal-title":"Eur J Pharmacol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830896X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830896X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:36Z","timestamp":1759400796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1830896X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":49,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X1830896X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation of a recombinant Newcastle disease virus expressing two foreign genes for use as a multivalent vaccine and gene therapy vector","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}